TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Employees - 209,
CEO - Mr. Antony Koblish,
Sector - Healthcare,
Country - US,
Market Cap - 52.61M
Altman ZScore(max is 10): -6.2, Piotroski Score(max is 10): 3, Working Capital: $53209000, Total Assets: $77251000, Retained Earnings: $-369994000, EBIT: -38359000, Total Liabilities: $59128000, Revenue: $71217000
- Current Price $1.33 - Analyst Target Price $5.60| Ticker | TELA |
| Index | - |
| Curent Price | 1.33 |
| Change | 15.65% |
| Market Cap | 52.61M |
| Average Volume | 252.29K |
| Income | -43.44M |
| Sales | 71.22M |
| Book Value/Share | 0.46 |
| Cash/Share | 1.08 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 209 |
| Moving Avg 20days | 31.28% |
| Moving Avg 50days | 4.71% |
| Moving Avg 200days | -45.28% |
| Shares Outstanding | 39.55M |
| Earnings Date | May 08 AMC |
| Inst. Ownership | 58.44% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 0.74 |
| Price/Book | 2.90 |
| Price/Cash | 1.23 |
| Price/FCF | - |
| Quick Ratio | 3.40 |
| Current Ratio | 4.22 |
| Debt/Equity | 2.31 |
| Return on Assets | -58.28% |
| Return on Equity | -267.29% |
| Return on Investment | -73.14% |
| Gross Margin | 66.93% |
| Ops Margin | -55.83% |
| Profit Margin | -61.00% |
| RSI | 65.17 |
| BETA(β) | 0.70 |
| From 52week Low | 53.85% |
| From 52week High | -79.54% |
| EPS | -1.41 |
| EPS next Year | -0.41 |
| EPS next Qtr | -0.18 |
| EPS this Year | 46.53% |
| EPS next 5 Year | - |
| EPS past 5 Year | 12.91% |
| Sales past 5 Year | 35.99% |
| EPS Y/Y | 15.53% |
| Sales Y/Y | 12.78% |
| EPS Q/Q | -8.03% |
| Sales Q/Q | 11.55% |
| Sales Surprise | 6.69% |
| EPS Surprise | -27.55% |
| ATR(14) | 0.12 |
| Perf Week | 35.71% |
| Perf Month | 49.44% |
| Perf Quarter | -53.82% |
| Perf Year | -79.09% |
| Perf YTD | -55.96% |
| Target Price | 5.60 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer